Mechanism of action
Hydrocodone is a semi-synthetic opioid that acts primarily as an agonist at mu-opioid receptors (MOR) in the central nervous system and peripheral tissues. Activation of mu-opioid receptors inhibits adenylyl cyclase, decreases intracellular cAMP, and reduces calcium influx while increasing potassium conductance. This results in hyperpolarization of neurons and decreased neurotransmitter release, particularly substance P and glutamate.
In the CNS, mu-receptor activation in the periaqueductal gray, rostral ventromedial medulla, and spinal dorsal horn modulates ascending pain pathways and produces analgesia. Hydrocodone also acts on opioid receptors in the medullary cough center to suppress the cough reflex. The drug undergoes hepatic metabolism via CYP2D6 to hydromorphone, a more potent mu-agonist that contributes significantly to analgesic effect.
Receptor selectivity
Hydrocodone has higher affinity for mu-opioid receptors than for kappa or delta receptors. The mu-receptor binding is responsible for both therapeutic effects (analgesia, antitussive action) and adverse effects (respiratory depression, euphoria, physical dependence, constipation). Individuals with CYP2D6 polymorphisms may experience altered drug response—poor metabolizers have reduced analgesia, while ultra-rapid metabolizers have increased risk of toxicity.
- Hydrocodone is a Schedule II controlled substance with high abuse potential; reclassified from Schedule III in 2014
- Metabolized by CYP2D6 to hydromorphone (more potent active metabolite); CYP2D6 poor metabolizers have reduced analgesia
- Combination products with acetaminophen create hepatotoxicity risk in overdose; maximum daily acetaminophen dose is critical
- Respiratory depression is the primary cause of opioid overdose death; risk increased with CNS depressants especially benzodiazepines
- Constipation does not develop tolerance; prophylactic bowel regimen required for chronic therapy
- Chronic use causes physical dependence requiring gradual taper to avoid withdrawal syndrome
- Neonatal opioid withdrawal syndrome occurs with chronic maternal use during pregnancy; potentially life-threatening
- Naloxone should be prescribed to patients at high risk of overdose and caregivers trained in its use
Indications
Hydrocodone is FDA-approved for the following conditions:
Analgesia: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. In the United States, hydrocodone is formulated in combination products with acetaminophen or ibuprofen for pain management. Extended-release single-agent hydrocodone formulations are reserved for chronic pain requiring around-the-clock opioid therapy.
Antitussive therapy: Hydrocodone is used for severe nonproductive cough unresponsive to non-opioid antitussives. Combination products with homatropine or chlorpheniramine are available for cough suppression. This indication is less commonly utilized due to concerns about abuse and regulatory restrictions.
Off-label uses
Hydrocodone has limited accepted off-label uses due to its controlled substance status and abuse potential. It is not recommended for routine cough suppression or mild pain where non-opioid alternatives are available.
Pharmacokinetics
Absorption: Hydrocodone is well absorbed from the gastrointestinal tract with oral bioavailability ranging from 70% to 85%. Peak plasma concentrations occur approximately 1.3 hours after immediate-release formulations and 14-16 hours after extended-release products. Food may delay absorption but does not significantly affect total bioavailability.
Distribution: The volume of distribution is approximately 3.3 to 4.7 L/kg. Hydrocodone crosses the blood-brain barrier and placenta, and is excreted in breast milk. Plasma protein binding is low at approximately 36%.
Metabolism: Hydrocodone undergoes extensive hepatic metabolism primarily via CYP2D6 to hydromorphone (active metabolite with greater potency) and via CYP3A4 to norhydrocodone (less active). Hydromorphone contributes significantly to the analgesic effect. Genetic polymorphisms in CYP2D6 result in variable metabolizer phenotypes affecting drug efficacy and toxicity risk.
Elimination: Metabolites are excreted primarily in urine. The elimination half-life of immediate-release hydrocodone is approximately 3.8 to 4.5 hours, while extended-release formulations have half-lives of 7 to 9 hours. Renal impairment may prolong elimination and increase drug accumulation.
Adverse effects
Hydrocodone produces adverse effects typical of mu-opioid receptor agonists. The severity increases with dose and duration of therapy.
Common adverse effects
- Constipation: Most common side effect, occurs in majority of patients due to decreased GI motility via mu-receptor activation in enteric nervous system; does not develop tolerance
- Nausea and vomiting: Stimulation of chemoreceptor trigger zone; often improves with continued use
- Sedation and drowsiness: CNS depression; caution with driving and operating machinery
- Dizziness and lightheadedness: May be exacerbated by orthostatic hypotension
- Pruritus: Histamine release and central opioid receptor-mediated mechanisms
Serious adverse effects
Respiratory depression: Life-threatening complication resulting from decreased responsiveness of brainstem respiratory centers to CO₂. Risk increases with higher doses, combination with other CNS depressants, and in opioid-naïve patients. This is the primary cause of opioid overdose mortality.
Physical dependence and withdrawal: Chronic use leads to neuroadaptation. Abrupt discontinuation precipitates withdrawal syndrome (lacrimation, rhinorrhea, mydriasis, piloerection, diaphoresis, diarrhea, yawning, insomnia, myalgias). Tapering is required when discontinuing prolonged therapy.
Addiction and abuse: Hydrocodone is a Schedule II controlled substance with high abuse potential. Euphoric effects and rapid development of tolerance drive misuse. Combination with acetaminophen was historically intended to reduce abuse but has led to acetaminophen-related hepatotoxicity in overdose.
Adrenal insufficiency: Chronic opioid use suppresses hypothalamic-pituitary-adrenal axis. Presents with fatigue, weakness, nausea, hypotension.
Androgen deficiency: Long-term use decreases testosterone and libido; may cause erectile dysfunction and amenorrhea.
Serotonin syndrome: Rare but serious when combined with serotonergic drugs (SSRIs, SNRIs, MAOIs).
Combination product toxicity
Hydrocodone formulations containing acetaminophen carry risk of hepatotoxicity if maximum daily acetaminophen dose (typically 3-4 grams) is exceeded. Acute liver failure can occur with acetaminophen overdose, requiring N-acetylcysteine treatment.
Contraindications and warnings
Absolute contraindications
- Known hypersensitivity to hydrocodone or any formulation component
- Significant respiratory depression or acute/severe bronchial asthma in unmonitored settings without resuscitative equipment
- Paralytic ileus or gastrointestinal obstruction
- Concurrent or recent use of MAO inhibitors (within 14 days)
Black Box Warnings
The FDA requires black box warnings for all opioid analgesics including hydrocodone:
Addiction, abuse, and misuse: Hydrocodone exposes patients to risks of addiction even at therapeutic doses. Assess patient risk prior to prescribing and monitor regularly.
Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation and after dose increases. Instruct patients on proper use.
Accidental ingestion: Accidental ingestion, especially in children, can result in fatal overdose.
Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy can cause withdrawal syndrome in the neonate, which may be life-threatening if not recognized and treated.
Cytochrome P450 3A4 interaction: Concomitant use with CYP3A4 inhibitors or discontinuation of CYP3A4 inducers may result in fatal overdose.
Concomitant use with benzodiazepines or CNS depressants: Combination increases risk of profound sedation, respiratory depression, coma, and death. Reserve for patients lacking alternative options.
Risks from combination with acetaminophen: Formulations containing acetaminophen have been associated with acute liver failure, particularly at doses exceeding recommendations or with alcohol use.
Special populations
Pregnancy: Opioids cross the placenta. Chronic use during pregnancy causes neonatal opioid withdrawal syndrome. Use only if benefits outweigh risks. Avoid during labor as it may prolong labor and cause neonatal respiratory depression.
Breastfeeding: Hydrocodone is excreted in breast milk. Due to risk of serious adverse reactions in nursing infants including sedation and respiratory depression, carefully weigh benefits. Monitor infant for increased sleepiness, breathing difficulties, or limpness.
Elderly patients: Increased sensitivity to opioid effects including respiratory depression. Start with reduced doses.
Hepatic impairment: Reduced metabolism increases drug exposure. Use with caution and consider dose reduction.
Renal impairment: Accumulation of metabolites occurs. Dose adjustment may be necessary.
Drug interactions
Hydrocodone has clinically significant interactions with multiple drug classes, primarily involving pharmacodynamic effects and CYP450 metabolism.
CNS depressants
Benzodiazepines, alcohol, barbiturates, sedative-hypnotics, other opioids: Additive CNS and respiratory depression. This combination significantly increases risk of profound sedation, respiratory depression, coma, and death. Avoid concomitant use when possible; if necessary, use lowest effective doses and monitor closely.
General anesthetics, phenothiazines, tranquilizers, muscle relaxants: Enhanced sedation and respiratory depression. Reduce doses of one or both agents.
Serotonergic drugs
SSRIs, SNRIs, TCAs, MAOIs, triptans, tramadol: Risk of serotonin syndrome (agitation, hyperthermia, hyperreflexia, clonus, autonomic instability). MAOIs are contraindicated within 14 days of hydrocodone use due to risk of severe reactions including hyperpyrexia and coma.
CYP450 interactions
CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir, grapefruit juice): Decrease hydrocodone metabolism, increasing plasma concentrations and risk of respiratory depression. May require dose reduction.
CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort): Increase hydrocodone metabolism, decreasing efficacy and potentially causing withdrawal in dependent patients. May require dose increase or discontinuation of inducer.
CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine, bupropion): Reduce conversion to hydromorphone (active metabolite), potentially decreasing analgesic efficacy in some patients. Clinical significance varies.
Anticholinergic drugs
Antihistamines, antipsychotics, antiparkinsonian drugs: Increased risk of urinary retention, severe constipation, paralytic ileus.
Mixed agonist-antagonist opioids
Nalbuphine, butorphanol, pentazocine: May reduce analgesic effect of hydrocodone and precipitate withdrawal in opioid-dependent patients. Avoid concurrent use.
Diuretics and antihypertensives
Opioids may reduce efficacy by inducing histamine release and causing vasodilation or by causing fluid retention.
Warfarin
Combination products containing acetaminophen may enhance anticoagulant effect of warfarin, increasing INR. Monitor coagulation parameters.
Clinical pearls
- Schedule II status: Hydrocodone was reclassified from Schedule III to Schedule II in 2014 in the United States due to escalating abuse. This limits refills and requires written prescriptions (though electronic prescribing is now permitted with DEA compliance).
- Acetaminophen ceiling effect: Combination products with acetaminophen create a dosing ceiling due to maximum safe daily acetaminophen dose (typically 3,000-4,000 mg). Exceeding this limit significantly increases hepatotoxicity risk.
- CYP2D6 genetic variability: Approximately 5-10% of Caucasians are CYP2D6 poor metabolizers and may experience reduced analgesia from hydrocodone due to decreased conversion to the active metabolite hydromorphone. Conversely, ultra-rapid metabolizers have increased risk of toxicity due to excessive production of hydromorphone.
- Naloxone co-prescribing: Prescribe naloxone for patients at increased risk of overdose (high-dose opioid therapy, concurrent benzodiazepine use, history of overdose, substance use disorder). Train patients and caregivers in naloxone administration.
- Constipation prophylaxis: Unlike other opioid side effects, constipation does not develop tolerance. Start a prophylactic bowel regimen (stimulant laxative plus stool softener) when initiating chronic therapy.
- Tapering for cessation: Patients on chronic hydrocodone therapy have developed physical dependence. Taper dose gradually (typically 10-25% reduction every 2-4 weeks) to prevent withdrawal syndrome. Faster tapers may be appropriate in supervised settings.
- Urine drug screening: Hydrocodone may not be detected by all immunoassay screens that detect "opiates" as these often target morphine metabolites. Specific testing for hydrocodone or use of chromatography methods may be necessary for monitoring compliance or detecting misuse.
- Not first-line for cough: With increased awareness of opioid risks, hydrocodone is reserved for severe refractory cough only. Non-opioid antitussives should be tried first.
- Extended-release formulations: Single-entity extended-release hydrocodone products are indicated only for severe chronic pain requiring continuous around-the-clock therapy. They are not for as-needed use and carry higher abuse and overdose risks if manipulated (crushing, chewing).
- Opioid REMS (Risk Evaluation and Mitigation Strategy): Prescribers should be familiar with the FDA's opioid REMS program, which includes education on appropriate prescribing, pain management, and safe storage and disposal.
Hydrocodone Hazards - Remember serious risks with "ABCDE": Addiction potential (Schedule II), Breathing depression (respiratory), Constipation (guaranteed), Dependence develops (physical), Extreme caution with CNS depressants (especially benzodiazepines)
Practice questions
1. A 45-year-old man with chronic back pain has been taking hydrocodone-acetaminophen 10-325 mg, two tablets four times daily for 6 months. He presents to the emergency department with confusion, asterixis, and jaundice. Laboratory studies show AST 2,340 U/L, ALT 2,180 U/L, INR 3.2, and total bilirubin 4.8 mg/dL. Acetaminophen level is 185 mcg/mL. What is the most likely explanation for this patient's presentation?
2. A 62-year-old woman with osteoarthritis has been taking hydrocodone-acetaminophen for pain control. She is also prescribed alprazolam for anxiety. She is brought to the emergency department by family members who found her unresponsive. On examination, she has pinpoint pupils, respiratory rate of 6 breaths/min, and oxygen saturation of 82% on room air. Blood pressure is 90/60 mmHg. Which of the following best explains the mechanism of her respiratory depression?
3. A 28-year-old man who has been taking prescribed hydrocodone for 8 months after a severe motor vehicle accident decides to stop the medication abruptly. Forty-eight hours later, he presents to the clinic with lacrimation, rhinorrhea, dilated pupils, sweating, diarrhea, and severe muscle aches. Vital signs show blood pressure 152/96 mmHg, heart rate 108/min, and temperature 37.8°C (100°F). What is the most appropriate next step in management?
Frequently asked questions
How does hydrocodone work?
Hydrocodone works by binding to mu-opioid receptors in the brain and spinal cord, blocking pain signals and altering pain perception. It is metabolized by the liver enzyme CYP2D6 to hydromorphone, a more potent active metabolite that contributes significantly to its pain-relieving effects. The drug also acts on opioid receptors in the cough center of the brain to suppress cough reflex.
What are the side effects of hydrocodone?
Common side effects include constipation (most frequent), nausea, drowsiness, dizziness, and itching. Serious side effects include life-threatening respiratory depression (slowed or stopped breathing), physical dependence with withdrawal symptoms upon stopping, addiction and abuse potential, low blood pressure, and hormonal problems (low testosterone, adrenal insufficiency) with chronic use. Combination products with acetaminophen carry risk of liver damage if maximum doses are exceeded.
Is hydrocodone a controlled substance?
Yes, hydrocodone is a Schedule II controlled substance in the United States as of 2014, when it was reclassified from Schedule III. Schedule II designation indicates high potential for abuse that may lead to severe psychological or physical dependence. This classification requires written or electronically transmitted prescriptions with no refills permitted, and stricter storage and record-keeping requirements for pharmacies and prescribers.
Hydrocodone vs oxycodone: what is the difference?
Both are semi-synthetic opioid analgesics used for moderate to severe pain, but they differ in potency and metabolism. Oxycodone is approximately 1.5 times more potent than hydrocodone milligram-per-milligram. Hydrocodone requires CYP2D6 metabolism to its active form (hydromorphone), making it subject to genetic variability, while oxycodone has intrinsic activity and is metabolized differently. Both are Schedule II controlled substances. In the US, hydrocodone is commonly combined with acetaminophen or ibuprofen, while oxycodone is available both alone and in combinations.
Can you take hydrocodone while pregnant or breastfeeding?
Hydrocodone should be used during pregnancy only if benefits clearly outweigh risks. Chronic use during pregnancy causes neonatal opioid withdrawal syndrome in newborns, which can be life-threatening and requires recognition and treatment. Use during labor may prolong labor and cause respiratory depression in the newborn. Hydrocodone passes into breast milk and can cause sedation, breathing problems, and limpness in nursing infants. The decision to breastfeed while taking hydrocodone should carefully weigh benefits against risks, with close monitoring of the infant required.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: R05DA03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.